Glenmark Pharma Q3FY17 Results : Impressive bottomline growth

Bhagyashree Vivarekar / 02 Feb 2017

Glenmark Pharma Q3FY17 Results : Impressive bottomline growth

The company's PAT of Rs. 711.3 crore represents a sequential QoQ increase of 27.98 per cent and a YoY increase of 170.35 per cent.

Glenmark Pharmaceuticals Ltd. reported its  consolidated results for the quarter ended December 31, 2016, today. 

The company’s sales for Q3FY17 were Rs 2191.7 crore, which represent a 0.93 per cent sequential increase and 54.76 per cent YoY increase.

Its operating profit (EBIT) for the quarter was Rs 818 crore and its EBIT margin was 37.32 per cent.

The company's PAT of Rs. 711.3 crore represents a sequential QoQ increase of 27.98 per cent and a YoY increase of 170.35 per cent.

Genmark Pharmaceuticals Ltd is a global integrated pharmaceutical company having presence in branded generic markets. The company is engaged in the discovery of new molecules. The company operates in one segment, viz. pharmaceuticals. The company’s drug discovery is focused in the areas of inflammation [asthma/COPD, rheumatoid arthritis etc.], metabolic disorders [diabetes, obesity, etc.] and pain [neuropathic pain and inflammatory pain].

If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.